An FDA advisory committee unanimously recommended Thursday that the next COVID vaccine should be a monovalent one in the JN.1 ...

Advisers to the FDA will debate if the virus has mutated enough since last winter to require a tweak to the formula.

The notice came shortly after an advisory panel meeting at which members debated the pros and cons of asking manufacturers to ...

The FDA’s recent activities regarding Covid-19 vaccines stray far from the well-established standards of vaccine regulatory ...

Advisers to the Food and Drug Administration met Thursday to help decide which variant of the virus that causes COVID should ...